Australian owned & operatedAustralian flag

Tesamorelin vs Ipamorelin | Research Comparison

Research Use Only: All compounds referenced on this page are intended strictly for in-vitro laboratory research purposes only. Not for human consumption, medical treatment, or veterinary use. Read our full disclaimer.

Tesamorelin and Ipamorelin are both growth hormone secretagogues used in laboratory research, but they act on entirely different receptors and through distinct mechanisms. Tesamorelin is a GHRH analogue that activates GHRH receptors on pituitary somatotrophs, while Ipamorelin is a selective GHS-R1a agonist that activates the ghrelin receptor. This comparison helps researchers understand the mechanistic differences and select the appropriate compound for their experimental design.

At a Glance

Property Tesamorelin Ipamorelin
Receptor target GHRH receptor (GHRHR) Ghrelin receptor (GHS-R1a)
Peptide class GHRH analogue (44 AA) GH secretagogue pentapeptide (5 AA)
Mechanism Stimulates GH synthesis and pulsatile release via GHRHR Stimulates GH release via GHS-R1a; cAMP/PKA and IP3/PKC pathways
Selectivity GHRHR-selective Highly selective GHS-R1a; minimal cortisol/prolactin effect
Primary research focus Visceral adipose tissue, GH/IGF-1 axis, hypothalamic-pituitary research GHS-R pharmacology, GH pulse dynamics, ghrelin receptor biology
Cortisol/ACTH effect Minimal at research concentrations Minimal — high selectivity profile
Molecular weight ~5136 Da ~711 Da
Combined use Used as standalone GHRHR agonist Frequently combined with CJC-1295 for dual-receptor GH research

Mechanism of Action

Tesamorelin

Tesamorelin is a full-length GHRH analogue (44 AA) with a trans-3-hexenoic acid N-terminal modification that confers DPP-IV resistance. It binds to GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and pulsatile secretion via cAMP/PKA signalling. In laboratory models, Tesamorelin-stimulated GH release drives hepatic IGF-1 production, enabling study of the complete GH/IGF-1 axis including downstream anabolic and lipolytic signalling.

Ipamorelin

Ipamorelin binds selectively to GHS-R1a (ghrelin receptor) on somatotroph cells, stimulating GH release through a mechanism distinct from GHRHR signalling. Its high receptor selectivity means it does not significantly stimulate ACTH, cortisol or prolactin in laboratory models. Ipamorelin is used to study GHS-R1a pharmacology, receptor internalisation and the ghrelin-independent GH secretagogue pathway in isolation from GHRHR-mediated effects.

Key Research Differences

Receptor Pathway

The fundamental distinction is receptor target. Tesamorelin activates GHRHR — the receptor for endogenous GHRH — while Ipamorelin activates GHS-R1a, the ghrelin receptor. These are independent signalling pathways. For experiments studying GHRHR pharmacology or native GHRH receptor interactions, Tesamorelin is the appropriate tool. For GHS-R1a pharmacology and ghrelin receptor biology, Ipamorelin is preferred.

Research Application Focus

Tesamorelin is primarily used in laboratory models studying visceral adipose tissue regulation, GH-mediated lipolysis and hypothalamic-pituitary axis function. Its full-length GHRH sequence makes it a close structural analogue to endogenous GHRH. Ipamorelin is primarily used in GH secretagogue pharmacology research, ghrelin receptor biology and combination GH secretagogue studies alongside CJC-1295 No DAC.

Combination Research

Ipamorelin is the standard GHS-R1a companion to CJC-1295 No DAC in dual-receptor GH secretagogue research. Tesamorelin is not typically used in combination protocols — it is used as a standalone GHRHR agonist. For researchers studying synergistic GH secretagogue effects via dual receptor activation, Ipamorelin (with CJC-1295) is the appropriate design. For standalone GHRHR research, Tesamorelin is preferred.

Choosing Between Them for Research

For GHRHR pharmacology, visceral adipose tissue research, full-length GHRH receptor interactions or hypothalamic-pituitary axis studies, Tesamorelin is the appropriate tool. For GHS-R1a pharmacology, ghrelin receptor biology, selective GH secretagogue research or combination protocols with CJC-1295, Ipamorelin is preferred. Both are available from Solatide Biosciences, independently third-party tested to ≥99% purity.

Related Resources


Research Use Only: All compounds are manufactured for in-vitro laboratory research and are not intended for human consumption, medical use, or veterinary applications. Full disclaimer.

Cart

0

Your cart is currently empty.